Evaluating LY4170156 for advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the safety, tolerability, and effectiveness of the drug LY4170156 in patients with selected advanced solid tumors. It is structured in two parts: a phase Ia for dose-escalation and optimization, followed by a phase Ib for dose-expansion. The trial aims to enroll participants with various types of cancers, including ovarian, endometrial, cervical, non-small cell lung, and triple-negative breast cancers. The study is expected to last approximately four years.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Have one of the following solid tumor cancers:

  * Dose Escalation: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer, endometrial cancer, cervical cancer, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), pancreatic cancer, or colorectal cancer (CRC)
  * Dose Optimization: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) and endometrial cancer
  * Dose Expansion: Low grade serous ovarian cancer, cervical cancer, NSCLC, TNBC, and high grade endometrioid cancer

Exclusion Criteria:

* Individual with known or suspected uncontrolled central nervous system (CNS) metastases
* Individual with history of carcinomatous meningitis
* Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
* Individual with evidence of corneal keratopathy or history of corneal transplant
* Any serious unresolved toxicities from prior therapy
* Significant cardiovascular disease
* Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)
* History of pneumonitis/interstitial lung disease
* Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention

Where it's running

• HonorHealth
  Scottsdale, Arizona, United States Recruiting
• University of California, San Diego (UCSD) - Moores Cancer Center
  La Jolla, California, United States Recruiting
• Emory University
  Atlanta, Georgia, United States Recruiting
• South Texas Accelerated Research Therapeutics (START) Midwest
  Grand Rapids, Michigan, United States Recruiting
• NYU Langone Health - Long Island
  Mineola, New York, United States Recruiting
• New York University (NYU) Clinical Cancer Center
  New York, New York, United States Recruiting

Study contacts

• Study coordinator: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
• Email: LillyTrials@Lilly.com
• Phone: 1-317-615-4559

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing UCB4594 for advanced cancer treatment

  This study is testing a new drug called UCB4594 to see if it can help treat advanced cancer by targeting a specific protein on cancer cells.

  Recruiting at 3 sites Phase 1/2 Cancer Research UK · London and 3 other locations · NCT06380816

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

• Testing DM002 in patients with advanced solid tumors

  This study is testing a new drug called DM002 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting at 7 sites Phase 1/2 Doma Biopharmaceutical（Suzhou）Co., Ltd. · San Francisco, California and 6 other locations · NCT06751329

• Evaluating NKT3964 for Adults with Advanced Solid Tumors

  This study is testing a new drug called NKT3964 to see if it can safely help adults with advanced solid tumors, like ovarian or triple-negative breast cancer, after other treatments have failed.

  Recruiting at 17 sites Phase 1 NiKang Therapeutics, Inc. · Little Rock, Arkansas and 20 other locations · NCT06586957

• Combination of trastuzumab and pertuzumab for treating cancers with HER2 mutations

  This study is testing if a combination of two cancer drugs, trastuzumab and pertuzumab, can help adults and young people with cancers that have HER2 mutations or amplifications.

  Recruiting at 24 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT05786716

• Combination of vemurafenib and cobimetinib for treating BRAF positive cancers

  This study is testing if the combination of vemurafenib and cobimetinib can help adults with different types of cancers that have a specific BRAF mutation.

  Recruiting at 16 sites Phase 2/3 Cancer Research UK · Belfast and 15 other locations · NCT05768178

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.